Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Emerging Healthcare Executes Option Agreement With ThromboVision

For a new diagnostic test to treat heart disease

Emerging Healthcare Solutions has reported the execution of an exclusive option agreement with ThromboVision, which has developed and patented T-Guide, a new diagnostic test to assist medical professionals with the treatment of heart disease.

Thrombovision said that its T-Guide could save thousands of lives by quickly helping healthcare professionals personalize their patients’ anti-platelet treatment, to help decrease the chances of a patient suffering a recurred heart attack or stroke. The T-Guide test provides near instantaneous information as to the effectiveness of treatments. The T-Guide provides a simple, inexpensive diagnostic test that can show a patient’s level of platelet stickiness, and their responsiveness to their prescribed treatments.

The option agreement gives the companies a mutual due diligence review period prior to completing an investment and profit sharing agreement. The emphasis in future health care will be on cost control while maintaining quality care from physicians.

Edward Teitel, president of ThromboVision, said: “We are excited about the opportunity to work with Emerging Healthcare Solutions to bring this important medical technology to cardiac patients worldwide.”